Clinical trial
Pemetrexed and Gemcitabine in Patients With Advanced Non-Small Cell Lung Cancer…
NCT00071136 · Eli Lilly and Company, Industry · Completed
Key facts
| NCT number | NCT00071136 |
|---|---|
| Title | Pemetrexed and Gemcitabine in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) |
| Official title | Phase 1/2 Dose-Escalating Study of Biweekly Alimta and Gemcitabine in Patients With Advanced Cancer |
| Lead sponsor | Eli Lilly and Company, Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Lung Neoplasms |
| Intervention type | Drug |
| Interventions | pemetrexed, gemcitabine |
| Enrollment | 48 |
| Start date | Dec 1, 2003 |
| Completion | Aug 1, 2006 |
| First posted | Oct 16, 2003 |
| Last update posted | Jan 26, 2007 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: